SCHEMBL2470113

SCHEMBL2470113

COc1ccccc1C(=O)NC(C1(c2cccc(F)c2)CCCNCC1)S(N)(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 2/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 2/20 0.37
SLC6A9 P48067 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
HPGD P15428 1/20 0.36
KCNA3 P22001 1/20 0.36
CCR8 P51685 1/20 0.35
CASP3 P42574 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
ATM Q13315 1/20 0.35
CTSD P07339 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473766 0.97 SMN1; SMN2 (0.44) SMN1; SMN2RAB9ANPC1LMNAPKM
SCHEMBL2465586 0.91 SMN1; SMN2 (0.41) SMN1; SMN2RAB9ANPC1LMNAPKM
SCHEMBL2469920 0.90 GAA (0.41) SMN1; SMN2RAB9ANPC1LMNAPKM
SCHEMBL2468580 0.90 ALDH1A1 (0.44) RAB9ANPC1ALDH1A1KMT2AMEN1
SCHEMBL2470303 0.88 NPC1 (0.39) SMN1; SMN2RAB9ANPC1LMNAPKM
SCHEMBL2472840 0.88 GAA (0.44) SMN1; SMN2RAB9ANPC1LMNAPKM
SCHEMBL2472644 0.87 ALDH1A1 (0.39) SMN1; SMN2RAB9ANPC1ALDH1A1KMT2A
SCHEMBL2470694 0.86 ALDH1A1 (0.46) RAB9ANPC1ALDH1A1KMT2AMEN1
SCHEMBL2465813 0.86 RXFP1 (0.47) LMNASLC6A9RXFP1
SCHEMBL2465502 0.86 NPC1 (0.42) RAB9ANPC1LMNAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 SMN1; SMN2 4032/4885RAB9A 1780/4885NPC1 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.